
Advances in Cancer Research
Description
Key Features
- Provides the latest information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Readership
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology
Table of Contents
1. Epigenetic regulation of cancer stem cell and tumorigenesis
Kezhou Zhu, Victoria Xie and Suyun Huang
2. Vascular mimicry: Triggers, molecular interactions and in vivo models
Stephen L. Wechman, Luni Emdad, Devanand Sarkar, Swadesh K. Das and Paul B. Fisher
3. Biology, pathology, and therapeutic targeting of RAS
J. Matthew Rhett, Imran Khan and John P. O’Bryan
4. Cyclin D-CDK4/6 functions in cancer
Xueliang Gao, Gustavo W. Leone and Haizhen Wang
5. SPARC-p53: The double agents of cancer
Denise Camacho, Joana P. Jesus, António M. Palma, Sofia A. Martins, Alexandre Afonso, Maria Leonor Peixoto, Christopher J Pelham and Rajan Gogna
6. Giants and monsters: Unexpected characters in the story of cancer recurrence
Shai White-Gilbertson and Christina Voelkel-Johnson
7. Ca2+ as a therapeutic target in cancer
Scott Gross, Pranava Mallu, Hinal Joshi, Bryant Schultz, Christina Go and Jonathan Soboloff
Product details
- No. of pages: 330
- Language: English
- Copyright: © Academic Press 2020
- Published: July 26, 2020
- Imprint: Academic Press
- eBook ISBN: 9780128203286
- Hardcover ISBN: 9780128203279
About the Serial Volume Editors
Paul Fisher

Affiliations and Expertise
Kenneth Tew

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.